AIMS: Gemcitabine has been associated with an increased risk of arterial and venous thromboembolic events (ATEs and VTEs), although the overall risk remains unclear. As indications for its use in oncology are expanding, a comprehensive characterization of these complications becomes imperative. METHODS: Pubmed was searched for articles published from 1 January 1990 to 31 December 2012. Eligible studies included prospective randomized controlled phase II and III trials evaluating gemcitabine based vs. non-gemcitabine based chemotherapy in patients with solid tumours. Data on VTEs and ATEs were extracted. Overall incidence rates, odds ratio (OR), and 95% confidence intervals (CIs) were calculated employing fixed or random effects models depending on the heterogeneity of included trials. RESULTS: A total of 4845 patients from 19 trials were included. Among patients treated with gemcitabine based chemotherapy, the overall incidence of VTEs (13 studies comprising 3823 patients) and ATEs (eight studies consisting of 2431 patients) was 2.1% (95% CI 1.2%, 3.8%) and 2.2% (95% CI 1.4%, 3.2%). The associated ORs of VTEs and ATEs were 1.56 (95% CI 0.86, 2.83, P = 0.15) and 1.82 (95% CI 0.89, 3.75, P = 0.10) compared with non-gemcitabine based therapy. A tendency to increase the risk of ATE and VTEs was also detected in any prespecified subgroup. CONCLUSION: The use of gemcitabine does not significantly increase the risk of VTEs and ATEs in patients with solid tumours when compared with non-gemcitabine based chemotherapy.
AIMS: Gemcitabine has been associated with an increased risk of arterial and venous thromboembolic events (ATEs and VTEs), although the overall risk remains unclear. As indications for its use in oncology are expanding, a comprehensive characterization of these complications becomes imperative. METHODS: Pubmed was searched for articles published from 1 January 1990 to 31 December 2012. Eligible studies included prospective randomized controlled phase II and III trials evaluating gemcitabine based vs. non-gemcitabine based chemotherapy in patients with solid tumours. Data on VTEs and ATEs were extracted. Overall incidence rates, odds ratio (OR), and 95% confidence intervals (CIs) were calculated employing fixed or random effects models depending on the heterogeneity of included trials. RESULTS: A total of 4845 patients from 19 trials were included. Among patients treated with gemcitabine based chemotherapy, the overall incidence of VTEs (13 studies comprising 3823 patients) and ATEs (eight studies consisting of 2431 patients) was 2.1% (95% CI 1.2%, 3.8%) and 2.2% (95% CI 1.4%, 3.2%). The associated ORs of VTEs and ATEs were 1.56 (95% CI 0.86, 2.83, P = 0.15) and 1.82 (95% CI 0.89, 3.75, P = 0.10) compared with non-gemcitabine based therapy. A tendency to increase the risk of ATE and VTEs was also detected in any prespecified subgroup. CONCLUSION: The use of gemcitabine does not significantly increase the risk of VTEs and ATEs in patients with solid tumours when compared with non-gemcitabine based chemotherapy.
Authors: Manfred P Lutz; Eric Van Cutsem; Theo Wagener; Jean-Luc Van Laethem; Udo Vanhoefer; Jacques A Wils; Eric Gamelin; Claus H Koehne; Jean P Arnaud; Emmanuel Mitry; Faress Husseini; Peter Reichardt; Mustafa El-Serafi; Pierre-Luc Etienne; Thomas Lingenfelser; Michel Praet; Bruno Genicot; Muriel Debois; Bernard Nordlinger; Michel P Ducreux Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Adam Brufsky; Karen Hoelzer; Thaddeus Beck; Robert Whorf; Mark Keaton; Padma Nadella; Elisa Krill-Jackson; Joan Kroener; Edward Middleman; Michael Frontiera; Devchand Paul; Timothy Panella; Jane Bromund; Luping Zhao; Mauro Orlando; Fritz Tai; Martin D Marciniak; Coleman Obasaju; John Hainsworth Journal: Clin Breast Cancer Date: 2011-07-01 Impact factor: 3.225
Authors: P A Kosmidis; G Fountzilas; A G Eleftheraki; H P Kalofonos; G Pentheroudakis; D Skarlos; M A Dimopoulos; D Bafaloukos; D Pectasides; E Samantas; J Boukovinas; S Lambaki; N Katirtzoglou; C Bakogiannis; K N Syrigos Journal: Ann Oncol Date: 2010-09-29 Impact factor: 32.976
Authors: Apurva A Desai; Nicholas J Vogelzang; Brian I Rini; Rafat Ansari; Stuart Krauss; Walter M Stadler Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Sara D'epiro; Monica Salvi; Carlo Mattozzi; Simona Giancristoforo; Marco Campoli; Ramona Zanniello; Cecilia Luci; Laura Macaluso; Sara Giovannoni; Roberto Iacovelli; Stefano Calvieri; Antonio Giovanni Richetta Journal: Case Rep Med Date: 2012-11-26
Authors: Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-11 Impact factor: 8.311